With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be statistically ...

Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent ...

Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue ...

Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...

Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...

Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...

Arcus Biosciences (RCUS) stock falls as the company and partner Gilead (GILD) halt a Phase 3 cancer trial evaluating its anti ...